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 25 
ABSTRACT 26 
Previously, we reported potent activity of a novel spiropyrimidinetrione, zoliflodacin, 27 
against N. gonorrhoeae isolates from symptomatic men in Nanjing, China, collected 28 
in 2013. Here, we investigated trends of susceptibilities of zoliflodacin in 986  29 
isolates collected from men between 2014 and 2018.  N. gonorrhoeae isolates were 30 
tested for susceptibility to zoliflodacin and seven other antibiotics. Mutations in gyrA, 31 
gyrB, parC, parE and mtrR genes were determined by PCR and sequencing. The MICs 32 
of zoliflodacin ranged from ≤0.002 to 0.25 mg/L; the overall MIC50s and MIC90s were 33 
0.06 mg/L and 0.125mg/L in 2018, increasing two-fold from 2014. However, the 34 
percent of isolates with lower zoliflodacin MICs declined in each year sequentially 35 
while the percent with higher MICs increased yearly (P≤0.00001). All isolates were 36 
susceptible to spectinomycin but resistant to ciprofloxacin (MIC ≥1 mg/L); 21.2% 37 
(209/986) were resistant to azithromycin (≥1 mg/L), 43.4% (428/986) were 38 
penicillinase-producing (PPNG), 26.9% (265/986) tetracycline-resistant (TRNG) and 39 
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 3 
19.4% (191/986) were multi-drug resistant (MDR) isolates. Among 202 isolates tested, 40 
all were quinolone resistant with double or triple mutations in gyrA; One hundred 41 
ninety three (193/202; 95.5%) also had mutations in parC. There were no D429N/A 42 
and/or K450T mutations in GyrB identified in the 143 isolates with higher zoliflodacin 43 
MICs; a S467N mutation in GyrB was identified in one isolate. We report that 44 
zoliflodacin continues to have excellent in vitro activity against clinical gonococcal 45 
isolates, including those with high-level resistance to ciprofloxacin, azithromycin and 46 
extended spectrum cephalosporins.  47 
 48 
INTRODUCTION 49 
Neisseria gonorrhoeae, the causative agent of the sexually transmitted infection 50 
gonorrhea, has developed resistance to all previously recommended antimicrobial 51 
agents for treatment, including sulfonamides, penicillins, tetracyclines and 52 
fluoroquinolones[1]. Currently, dual antimicrobial therapy with ceftriaxone 250 mg or 53 
cefixime 400 mg plus azithromycin 1g is recommended as first-line treatment of 54 
uncomplicated gonorrhea by the World Health Organization (WHO)[2] and ceftriaxone 55 
plus azithromycin by the U. S. Centers for Disease Control and Prevention (CDC)[3].  56 
Resistance to extended-spectrum cephalosporin (ESCs) and azithromycin is increasing 57 
worldwide. Gonococcal isolates with decreased susceptibility to cefixime and/or 58 
ceftriaxone have been reported in China[4], Japan[5], Australia[6], European countries[7] 59 
and the United States[8] and isolates with high-level resistance to ceftriaxone have 60 
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 4 
been identified in Japan, Australia, France, Spain, Denmark, Canada Ireland and 61 
China [9,10,11].  The reported prevalence of azithromycin-resistant N. gonorrhoeae 62 
isolates is 18.6% in China[4], 14.5% in Japan[5], 6.2% in Australia [6], 7.5% in 25 63 
European countries [7], 4.6% in the United States [8], and 6.1% in Western Africa[12]. 64 
The first documented case that failed treatment with the recommended dual therapy 65 
was reported from the UK in 2016 [13] and the first gonococcal isolates (the A2543 66 
clone) with combined ceftriaxone plus high-level azithromycin resistance were 67 
identified in the UK[14] and Australia[15] in 2018. 68 
Increased antimicrobial resistance (AMR) in N. gonorrhoeae poses an emerging 69 
global public health threat of untreatable gonococcal infections. New oral 70 
antimicrobial agents with activity against N. gonorrhoeae are needed urgently.  71 
WHO includes N. gonorrhoeae on its list of  “priority pathogens” that require new 72 
antibiotics for treatment[16] and the U.S. CDC has designated drug-resistant N. 73 
gonorrhoeae as an urgent threat [17].  Zoliflodacin (also known as AZD0914 and 74 
ETX0914) is a novel spiropyrimidinetrione bacterial DNA gyrase /topoisomerase 75 
inhibitor with broad-spectrum in vitro activity against gram-positive and fastidious 76 
gram-negative organisms, including N. gonorrhoeae.[18,19]. A recent multicenter, 77 
randomized, phase 2 clinical trial demonstrated that zoliflodacin was effective in 78 
treating gonococcal urogenital and rectal infections and supports a larger, more 79 
definitive study of zoliflodacin for the treatment of uncomplicated gonorrhea. [20]  80 
We showed previously that zoliflodacin was highly effective against clinical isolates of 81 
N. gonorrhoeae in vitro, including high-level ciprofloxacin-resistant and multidrug 82 
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 5 
resistant isolates, collected in 2013 in Nanjing, China[21]. Here, in vitro activities and 83 
trends of zoliflodacin susceptibilities were determined for clinical gonococcal isolates 84 
(including multidrug resistant isolates), collected between 2014 and 2018 in Nanjing.  85 
Mutations in the quinolone-resistance-determinant regions (QRDRs) of gyrA, parC, 86 
gyrB , parE and mtrR genes in were also determined for isolates across the 87 
zoliflodacin MIC distribution range. 88 
 89 
RESULTS 90 
Susceptibilities to zoliflodacin and other antimicrobials 91 
Susceptibilities (MICs) of N. gonorrhoeae to zoliflodacin and seven antimicrobials 92 
previously or currently used for the treatment of gonorrhea are summarized for the 93 
986 clinical isolates in Table 1. All isolates except one were inhibited by ≤0.125 mg/L 94 
of zoliflodacin (the remaining isolate had an MIC of 0.25mg/L).  MICs to zoliflodacin 95 
ranged from ≤0.002 to 0.25mg/L overall, with an MIC50 and MIC90 of  0.06 mg/L and 96 
0.125 mg/L, respectively. One hundred forty three (14.5%) isolates had zoliflodacin 97 
MICs at the upper end of the distribution range ( 0.125-0.25 mg/L) and 59 (6%) 98 
isolates had MICs in the lower end of the  MIC distribution range (≤0.002 99 
-0.015mg/L). The percent of isolates with an MIC of 0.03 mg/L to zoliflodacin 100 
declined in each year sequentially (χ2= 82.237, P=0.000) while the percent with MICs 101 
of 0.06 and 0.125 mg/L increased correspondingly (χ2= 20.739 and 41.717, 102 
respectively; P≤0.00001; Chi square test for linear trend), shown in Figure 1. Overall, 103 
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 6 
the proportion of isolates with zoliflodacin MICs 0.125-0.25 mg/L increased from 3.1% 104 
(6/197) in 2014 to 23.0% (47/204) in 2018 (χ2= 43.112, P<0.0001).  105 
All 986 isolates were resistant to ciprofloxacin; 777 (78.8%) showed high level 106 
resistance (≥16 mg/L)[22].  During the five year study period, the annual percentage 107 
of ciprofloxacin resistant isolates at each MIC point (from 1 mg/L to ≥16mg/L) did 108 
not shift in either direction in the 5-year period. MICs of gonococcal isolates for 109 
zoliflodacin were lower than ciprofloxacin (P<0.0001), with a median difference of at 110 
least 267-fold. Four hundred and twenty eight isolates (43.4%) were PPNG and 265 111 
(26.9%) were TRNG. The percent of penicillin-resistant isolates increased from 70% to 112 
86.3% over the five years (χ2= 17.641, P< 0.0001). Although all isolates were 113 
susceptible to spectinomycin, the percent of isolates with lower spectinomycin MICs 114 
(8 mg/L and 16 mg/L）declined (χ2= 16.35 and 93.71, P=0.0001 and P< 0.0001, 115 
respectively) while the percent with higher MICs (32mg/L) increased over the five 116 
years (χ2= 112.514 , P<0.0001). 117 
Two hundred and nine (21.2%) isolates were resistant to azithromycin (MIC≥118 
1mg/L), and 62 (6.3%) displayed high-level resistance (MIC≥256 mg/L). The percent 119 
of isolates with lower azithromycin MICs (0.06 mg/L and 0.125mg/L）increased over 120 
the five years（χ2= 16.916 and 22.099, respectively; P< 0.0001) while the percent with 121 
higher MICs (0.5mg/L and ≥1024 mg/L) declined yearly (χ2= 15.403 and 12.268, 122 
respectively; P<0.001). Overall, the percent of azithromycin-resistant isolates (MIC ≥123 
1mg/L) decreased from 27.9% to 15.2% over the five years and the percent of 124 
azithromycin-susceptible isolates increased from 72.1% to 84.8%  (χ2 = 14.618, P< 125 
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 7 
0.001).  One hundred and fifty eight isolates (15.2%) exhibited decreased 126 
susceptibility (MIC 0.125-0.25 mg/L, n=156) or resistance (MIC = 1mg/L, n=2) to 127 
ceftriaxone, and 102 isolates (10.1%) displayed decreased susceptibility (MIC 128 
0.25mg/L, n=64) or resistance (MIC 0.5mg/ L, n=36; MIC>2mg/L, n=2 ) to cefixime. 129 
The percent of isolates with lower ceftriaxone MICs (≤ 0.03mg/L）declined in each 130 
year sequentially（χ2= 10.512, P< 0.01) while the percent with higher MICs (0.06mg/L 131 
and 0.125 mg/L) increased yearly (χ2= 10.18 and 4.231, P<0.01 and P<0.05, 132 
respectively). The percent of isolates with lower cefixime MICs (0.015 mg/L and 0.03 133 
mg/L）declined (χ2= 23.324 and 10.734, P<0.001 and P<0.01, respectively) while the 134 
percent with higher MICs (0.06-0.5mg/L ) increased over the five years (χ2= 10.734, 135 
8.68, 14.683 and 20.056, P<0.05, ~P<0.0001, respectively).  One hundred ninety 136 
one (19.4%) isolates showed multidrug resistance (MDR).  The proportion of MDR 137 
isolates increased from 7.1% in 2014 to 27% in 2016, then decreased to 21.1% in 138 
2018 (χ2= 12.82, P=0.00034). The two MDR isolates with high level resistance to 139 
ceftriaxone (MIC 1.0 mg/L), cefixime (MIC ≥ 2.0 mg / L) , ciprofloxacin (MIC ≥ 140 
16mg/L) , penicillin (MIC 4 mg/L) and tetracycline (MIC 4mg/L) had low zoliflodacin 141 
MIC values (0.03 and 0.06 mg/L, respectively). 142 
  143 
Characterization of amino acid substitutions in GyrA, GyrB, ParC and ParE  144 
All 202 isolates tested were ciprofloxacin-resistant (MICs 2 to ≥ 16 mg/L).  All 145 
isolates had double or triple mutations in the gyrA gene. Both S91F and D95A/G/N/Y 146 
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 8 
amino acid substitutions in GyrA were identified in the 202 isolates. 16 (11.2%) of 147 
isolates in the higher zoliflodacin MIC distribution group and 2 (3.4%) in the lower 148 
MIC group also had an additional A92P amino acid substitution in GyrA.  ParC 149 
substitutions were observed in 97.2% of the isolates in the higher zoliflodacin MIC 150 
distribution group and 91.5% in the lower MIC group. Single, double and triple ParC 151 
substitutions were identified in 114 (79.7%), 22 (15.4%) and 3 (2.1%) of the isolates 152 
in higher MIC distribution group and 66.1%, 25.4% and 0 in the lower MIC group, 153 
respectively. The amino acid substitution at position S87 in the ParC, including S87C, 154 
S87I, S87N and S87R was present in 79.7% isolates in the higher MIC distribution 155 
group and 81.4% in the lower MIC group, respectively. The most common double 156 
substitutions in ParC were S87R plus S88P (10.7%) in the higher MIC group, and S87R 157 
plus G85D( 15.3%) in the lower MIC group. The three isolates in higher MIC group 158 
had the same triple substitutions (S87R, A123V and A129V). A89T, G120R, A123V and 159 
A129V mutations in ParC are newly described here. GyrB substitutions/insertions 160 
were identified in four isolates (two with V470I substitutions, one with a S467N 161 
substitution and one with an arginine (A) insertion at 480 [480A]) in the upper end of 162 
the MIC distribution group but none in low MIC group. All four isolates with a GyrB 163 
mutation had MIC values of 0.125 mg/L for zoliflodacin and 4 mg/L or greater for 164 
ciprofloxacin. Amino acid substitutions in ParE were identified in 57 isolates (39.9%) 165 
in the high zoliflodacin MIC distribution group. The most common single substitution 166 
in ParE was D437N, which was greater in isolates with MICs in the upper end of the 167 
zoliflodacin MIC distribution range (23.1%) than in the lower end of the range (6.78%) 168 
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 9 
(P<0.01). The overall frequency of amino acid substitutions in GyrA, GyrB, ParC and 169 
ParE was no different across the MIC distribution range (Table 2). 170 
Mutations in mtrR  171 
A number of single or multiple mutations were identified in the 202 isolates, 172 
including an adenosine (A) deletion in the mtrR promoter region, and mutations in 173 
the mtrR coding region that resulted in amino acid changes in MtrR: A39T, A40D, 174 
G45D, F62L, D79N, T86A, H105Y, and E117K mutations, singly or in combination 175 
(Supplemental Table 2). A total of 175 (86.6%) isolates carried the A deletion, 48 176 
(81.4%) in the low zoliflodacin MIC group and 127 (88.8%) in the high group 177 
(P=0.2346). There were no significant differences in the rates of individual mutations 178 
(singly or combined) in MtrR accompanied (or not) by an A deletion in the promoter 179 
region, except for an H105Y mutation accompanied by an A deletion in the promoter, 180 
which accounted for 62.7 % (37/59) of isolates with low zoliflodacin MICs and 41.3% 181 
(59/143) in the high zoliflodacin MIC group (P<0.01) (Supplemental Table 2). 182 
 183 
DISCUSSION  184 
We determined susceptibility trends in in vitro antibacterial activity of zoliflodacin 185 
and seven other antimicrobial agents against 986 clinical gonococcal isolates 186 
collected over a five-year period (2014-2018). The 986 gonococcal isolates were 187 
susceptible to zoliflodacin and all were resistant to ciprofloxacin. Nearly a quarter 188 
were resistant to azithromycin or were TRNG isolates. Greater than 40% were PPNG 189 
 on F
ebruary 1, 2021 at U
N
IV
 O
F
 M
A
S
S
 M
E
D
 S
C
H
http://aac.asm
.org/
D
ow
nloaded from
 
 10 
isolates and just under 20% were MDR isolates. All 986 isolates had zoliflodacin MICs 190 
below the breakpoint (MIC ≥ 0.5mg/L) that have been proposed, guided by clinical 191 
efficacy [20].  Similar to other reports [19,23], zoliflodacin exhibited an MIC range of 192 
0.002 to 0.25 mg/L and there was no correlation between zoliflodacin MICs at the 193 
upper end of the MIC range and ciprofloxacin-resistance [19, 24,25].  Furthermore, 194 
zoliflodacin exhibited low MICs (0.03 and 0.06mg/L) in two isolates that were fully 195 
resistant to ceftriaxone and cefixime. A modest temporal shift in the MICs to 196 
zoliflodacin was observed over the five year period. 197 
Zoliflodacin is a novel spiropyrimidinetrione bacterial DNA gyrase/ topoisomerase 198 
inhibitor, which prevents bacterial DNA biosynthesis and results in accumulation of 199 
double-strand cleavages through a mechanism distinct from that in fluoroquinolones 200 
[18,24,26].  In our study, all the ciprofloxacin-resistant zoliflodacin-sensitive isolates 201 
tested , displayed double or triple mutations in GyrA; greater than 90% had 202 
additional amino acid substitutions in ParC.   203 
    In contrast to fluoroquinolones, zoliflodacin inhibits the GyrB subunit of type II 204 
topoisomerase; specific mutations in GyrB can result in increased resistance to 205 
zoliflodacin [24,25].  We did not find mutations such as D429N, D429A or K450T 206 
alterations in GyrB, which have  been identified in vitro and select for resistant 207 
mutants that result in zoliflodacin MICs of 0.5–8 mg/L[24,25].  However, we found 208 
that 4/143 (2.8%) of gonococcal isolates at the upper end of the MIC distribution 209 
range MICs (0.125 and 0.25 mg/L) harbored a GyrB mutation, however the amino 210 
acid substitutions/insertions (S467N, V470I or 480A)  were not associated with 211 
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 11 
resistance. An S467N amino acid substitution in GyrB, which did not result in reduced 212 
susceptibility to zoliflodacin, has been reported in a clinical gonococcal isolate[19]. 213 
Mutations of V470I or 480A have not been reported previously in clinical isolates or 214 
in in vitro selected resistant mutants.  215 
  Mutations in mtrR , which result in overexpression of the MtrCDE efflux pump, can 216 
increase efflux of antimicrobials and reduce the susceptibility to numerous 217 
antimicrobials [26,27 ].  The MtrCDE efflux pump can also influence susceptibility to 218 
zoliflodacin[25].  Inactivation of the MtrCDE efflux pump has been shown to 219 
decrease the MIC of zoliflodacin in N. gonorrhoeae strain H041 strain from 0.125 to 220 
0.004 mg/L[25].  In our study, an adenine (A) deletion in the mtrR promoter and a 221 
number of mutations in MtrR (or both), were identified in isolates that possessed 222 
either lower or higher zoliflodacin MICs.  A single H105Y amino acid substitution 223 
was the most common substitution present in MtrR; this change was identified in 50% 224 
of the isolates. The single H105Y amino acid substitution, which lies outside the 225 
known DNA binding domain of MtrR, is generally thought not to be involved with 226 
active repressor function of MtrR; it has also been shown to be associated with N. 227 
gonorrhoeae isolates that are fully sensitive to ceftriaxone[28]. One possibility is that 228 
the H105Y mutation may interfere with MtrR dimerization resulting in a reduction of 229 
MtrR binding to target sequences[29]   230 
   Few studies have examined the impact of parE mutations on quinolone 231 
resistance in N. gonorrhoeae[30,31]. Clinical gonococcal isolates with P439S amino acid 232 
substitutions in ParE did not result in a significant increase in MIC to 233 
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 12 
ciprofloxacin[31,32] . The clinical relevance of the ParE mutations identified in our study 234 
is unclear . 235 
In conclusion, zoliflodacin demonstrated potent in vitro antibacterial activity 236 
against a recent collection of clinical gonococcal isolates from China (2014 to 2018), 237 
including isolates with high-level resistance to ciprofloxacin, azithromycin and 238 
extended spectrum cephalosporins.  Zoliflodacin MICs shifted upward temporally in 239 
the five-year period in the absence of clinical use. These results confirm the lack of   240 
pre-existing clinical resistance to zoliflodacin. Continued monitoring of antimicrobial 241 
susceptibility of zoliflodacin, a promising new oral antibacterial agent, for the 242 
treatment of uncomplicated gonorrhea is warranted .   243 
 244 
MATERIALS AND METHODS 245 
Bacterial isolates  From January 2014 to December 2018, a total of 986 gonococcal 246 
isolates were collected from male patients with symptomatic urethritis (urethral 247 
discharge and/or dysuria) attending the STD clinic at the Institute of Dermatology, 248 
Chinese Academy of Medical Sciences, Nanjing, China. All men except one reported 249 
that they were heterosexual. Urethral exudates were collected with cotton swabs, 250 
then immediately inoculated onto Thayer-Martin medium (Zhuhai DL Biotech, China) 251 
and cultured in candle jars at 36°C for 24–48 h. Gonococcal isolates were identified 252 
by colonial morphology, Gram’s stain and oxidase testing and growth on GC 253 
chocolate agar base (Difco, Detroit, MI) supplemented with 1% IsovitaleX™ (Oxoid, 254 
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 13 
USA) . Gonococcal colonies were suspended in tryptone-based soy broth and frozen 255 
(−70°C) until used for antimicrobial testing. 256 
Antimicrobial susceptibility testing  Zoliflodacin powder was provided by Entasis, 257 
Therapeutics, Waltham, MA. The minimum inhibitory concentrations (MICs; mg/L) of 258 
N. gonorrhoeae isolates to zoliflodacin, penicillin, tetracycline, ciprofloxacin, 259 
spectinomycin, azithromycin, cefixime and ceftriaxone were determined by the agar 260 
dilution method in accordance with the Clinical and Laboratory Standards Institute 261 
(CLSI) guidelines[33]. ATCC 49226, WHO reference strains F, G, L, O, and P were used 262 
as quality controls.  The MIC ranges of zoliflodacin for quality control (QC) strain ATCC 263 
49226 were 0.125-0.25mg/L in each antimicrobial susceptibility testing run in this 264 
study in accordance with the defined MIC QC ranges (0.06-0.5mg/L) for 265 
zoliflodacin[34].  Criteria for decreased susceptibility to ceftriaxone (MIC≥0.125 266 
mg/L) and cefixime (MIC≥0.25 mg/L) were defined by WHO[35].  Using CLSI[33] and 267 
EUCAST [36] (for azithromycin only) criteria, the following MIC breakpoints were used 268 
to ascertain resistance: ≥128 mg/L, spectinomycin; ≥2 mg/L, penicillin and 269 
tetracycline and ≥1 mg/L, ciprofloxacin and azithromycin.  The breakpoint for 270 
zoliflodacin of ≥0.5 mg/L was utilized as previously described [20].  Multi-drug 271 
resistant (MDR) N. gonorrhoeae was defined as decreased susceptibility or resistance 272 
to extended spectrum cephalosporins (ESCs), plus resistance to at least two of the 273 
following antimicrobials: penicillin; ciprofloxacin and azithromycin [37,38]. 274 
Identification of gene mutations that resulted in amino acid substitutions in GyrA, 275 
GyrB, ParC and ParE   276 
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 14 
One hundred forty three gonococcal isolates with zoliflodacin MICs (0.125mg/L and 277 
0.25mg/L) at the upper end of the MIC distribution range and 59 isolates with lower 278 
zoliflodacin MICs (≤0.002-0.015mg/L) were selected for genetic resistance 279 
determinants study. Mutations in the quinolone-resistance-determining regions 280 
(QRDR) of gyrA, gyrB, parC and parE genes were determined by PCR and DNA 281 
sequencing using primers described previously [39-41] (supplemental Table 1). Genomic 282 
DNA was extracted from gonococcal isolates using the Rapid Bacterial Genomic DNA 283 
Isolation Kit (DNA-EZ Reagents V All-DNA-Fast-Out, Sangon Biotech Co. Ltd, Shanghai). 284 
PCR amplification and sequencing of the genes were carried out by Nanjing Qingke 285 
Biotech Co. Ltd. 286 
Evaluation of mutations in the mtrR gene 287 
To identify mutations that potentially could cause enhanced expression of the 288 
MtrCDE-encoded efflux pump, mutations in the mtrR gene and  promoter region 289 
were identified by PCR. Sequencing of mtr genes from 202 isolates was performed as 290 
described previously [28] .  291 
 292 
Data Analysis 293 
Chi-square (χ2) testing was used to compare the rate of resistance in different years 294 
and Chi-square test for linear trends was used to assess the change in the MICs and 295 
the proportion of isolates resistant to antibiotics. SPSS version 19.0 was used for 296 
statistical analysis; P<0.05 was considered statistically significant.  297 
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 477 
Table 1. Susceptibilities and MICs of zoliflodacin and seven antimicrobials previously or 478 
currently used for treatment of gonorrhea against 986 clinical N. gonorrhoeae isolates. 479 
 
Antimicrobial  
No. (%) MIC (mg/L) 
Susceptible Intermediate Resistant Range MIC50 MIC90 
zoliflodacin 986（100）   ≤0.002 to 0.25 0.06 0.125 
Penicillin G     0 171 (17.3) 815 (82.7)  0.125 to ≥16 4 ≥16 
tetracycline    4 (0.4) 150 (15.2) 832 (84.4)  ≤0.125 to ≥32   2 ≥32 
ciprofloxacin 0 0 986 (100) 1 to ≥ 16 ≥16 ≥16 
azithromycin 551(55.9) 226 (22.9) 209 (21.2) ≤0.015 to ≥2048  0.5 4 
spectinomycin 986(100) 0 0  ≤4  to 32  32 32 
cefixime 948(96.1) - 38 (3.9) ≤0.002 to >2  0.03     0.25 
ceftriaxone    984(99.8) - 2 (0.2) ≤0.002 to 1  0.03 0.125 
MIC: minimum inhibitory concentration 480 
  481 
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Table 2. Comparison of amino acid substitutions in GyrA, GyrB, ParC and ParE in isolates with 482 
lower zoliflodacin MICs versus isolates with higher MICs  483 
Amino acid substitutions  
No.(%) of N. gonorrhoeae isolates 
P-valuec 
 lower zoliflodacin MICs 
group (n=59)a 
higher zoliflodacin MICs 
group (n=143)b 
GyrA 59(100.00%) 143(100.00%) NA 
S91F 59(100%) 143(100%)  
D95A/G/N/Y 59(100%) 143(100%)  
A92P 2(3.39%) 16(11.19%) 0.103 
D80N 1(1.69%) 0 0.292 
V81I 1(1.69%) 0 0.292 
ParC  54(91.53%) 139(97.20%) 0.13 
    G85C/D/A 14(23.73%) 7(4.90%) <0.001 
    D86N 3(5.08%) 20(13.99%) 0.088 
    S87C/I/N/R 48(81.36%) 114(79.72%) 0.943 
S88P 1(1.69%) 10(6.99%) 0.181 
A89T 1(1.69%) 1(0.70%) 0.499 
E91G 2(3.39%) 7(4.90%) 1.000 
G120R 0 2(1.40%) 1.000 
A123V 0 3(2.10%) 0.557 
A129V 0 3(2.10%) 0.557 
GyrB 0 4(2.80%) 0.32 
S467N 0 1 (0.70%) 1.000 
V470I 0 2 (1.40%) 1.000 
+480A 0 1 (0.70%) 1.000 
ParE 20(33.90%) 57(39.86%) 0.43 
D437H/N 5(8.47%) 34(23.78%) 0.01 
P456S 14(23.73%) 22(15.38%) 0.227 
P469L 0 1(0.70%) 1.000 
D425Y 1(1.69%) 0 0.292 
L462I 1(1.69%) 0 0.292 
a isolates with zoliflodacin MICs ≤0.002-0.015mg/L 484 
b isolates with zoliflodacin MICs 0.125-0.25mg/L 485 
c Determined by the χ2 or fisher exact test 486 
 487 
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 488 
 489 
Figure 1. MIC distributions of zoliflodacin for 986 clinical N. gonorrhoeae isolates (2014-2018). 490 
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